A liquid formulation for oral administration of the CETP inhibitor of formula (I) has improved bioavailability compared with conventional solid formulations. The formulation comprises the CETP inhibitor, or a pharmaceutically acceptable salt thereof; an oil; and one or more nonionic surfactants having a hydrophilic lipophilic balance (HLB)>10. ##STR00001##

 
Web www.patentalert.com

< SULFONAMIDES AS OREXIN ANTAGONISTS

> Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1

> TASTE TITRATION THERAPIES

~ 00533